A citation-based method for searching scientific literature

Jacopo Boni, Carlota Rubio-Perez, Nuria López-Bigas, Cristina Fillat, Susana de la Luna. Cancers (Basel) 2020
Times Cited: 27







List of co-cited articles
208 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications.
Ramzi Abbassi, Terrance G Johns, Michael Kassiou, Lenka Munoz. Pharmacol Ther 2015
96
25

Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation.
Nora Göckler, Guillermo Jofre, Chrisovalantis Papadopoulos, Ulf Soppa, Francisco J Tejedor, Walter Becker. FEBS J 2009
166
25

Activation, regulation, and inhibition of DYRK1A.
Walter Becker, Wolfgang Sippl. FEBS J 2011
140
25

Updating dual-specificity tyrosine-phosphorylation-regulated kinase 2 (DYRK2): molecular basis, functions and role in diseases.
Alejandro Correa-Sáez, Rafael Jiménez-Izquierdo, Martín Garrido-Rodríguez, Rosario Morrugares, Eduardo Muñoz, Marco A Calzado. Cell Mol Life Sci 2020
14
50

Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A.
Yasushi Ogawa, Yosuke Nonaka, Toshiyasu Goto, Eriko Ohnishi, Toshiyuki Hiramatsu, Isao Kii, Miyo Yoshida, Teikichi Ikura, Hiroshi Onogi, Hiroshi Shibuya,[...]. Nat Commun 2010
178
22

DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage.
Naoe Taira, Keishi Nihira, Tomoko Yamaguchi, Yoshio Miki, Kiyotsugu Yoshida. Mol Cell 2007
210
22

Inhibition of DYRK1A Stimulates Human β-Cell Proliferation.
Ercument Dirice, Deepika Walpita, Amedeo Vetere, Bennett C Meier, Sevim Kahraman, Jiang Hu, Vlado Dančík, Sean M Burns, Tamara J Gilbert, David E Olson,[...]. Diabetes 2016
114
18

Selectivity Profiling and Biological Activity of Novel β-Carbolines as Potent and Selective DYRK1 Kinase Inhibitors.
Katharina Rüben, Anne Wurzlbauer, Agnes Walte, Wolfgang Sippl, Franz Bracher, Walter Becker. PLoS One 2015
36
18

DYRK1A: the double-edged kinase as a protagonist in cell growth and tumorigenesis.
P Fernández-Martínez, C Zahonero, P Sánchez-Gómez. Mol Cell Oncol 2015
60
18

Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression.
Sourav Banerjee, Tiantian Wei, Jue Wang, Jenna J Lee, Haydee L Gutierrez, Owen Chapman, Sandra E Wiley, Joshua E Mayfield, Vasudha Tandon, Edwin F Juarez,[...]. Proc Natl Acad Sci U S A 2019
24
20

The selectivity of protein kinase inhibitors: a further update.
Jenny Bain, Lorna Plater, Matt Elliott, Natalia Shpiro, C James Hastie, Hilary McLauchlan, Iva Klevernic, J Simon C Arthur, Dario R Alessi, Philip Cohen. Biochem J 2007
18

Site-specific proteasome phosphorylation controls cell proliferation and tumorigenesis.
Xing Guo, Xiaorong Wang, Zhiping Wang, Sourav Banerjee, Jing Yang, Lan Huang, Jack E Dixon. Nat Cell Biol 2016
104
18

Structures of Down syndrome kinases, DYRKs, reveal mechanisms of kinase activation and substrate recognition.
Meera Soundararajan, Annette K Roos, Pavel Savitsky, Panagis Filippakopoulos, Arminja N Kettenbach, Jesper V Olsen, Scott A Gerber, Jeyanthy Eswaran, Stefan Knapp, Jonathan M Elkins. Structure 2013
97
18

Activation-loop autophosphorylation is mediated by a novel transitional intermediate form of DYRKs.
Pamela A Lochhead, Gary Sibbet, Nick Morrice, Vaughn Cleghon. Cell 2005
214
18

ATM augments nuclear stabilization of DYRK2 by inhibiting MDM2 in the apoptotic response to DNA damage.
Naoe Taira, Hiroyuki Yamamoto, Tomoko Yamaguchi, Yoshio Miki, Kiyotsugu Yoshida. J Biol Chem 2010
51
18

DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells.
Naoe Taira, Rei Mimoto, Morito Kurata, Tomoko Yamaguchi, Masanobu Kitagawa, Yoshio Miki, Kiyotsugu Yoshida. J Clin Invest 2012
94
18

The stress-responsive kinase DYRK2 activates heat shock factor 1 promoting resistance to proteotoxic stress.
Rita Moreno, Sourav Banerjee, Angus W Jackson, Jean Quinn, Gregg Baillie, Jack E Dixon, Albena T Dinkova-Kostova, Joanne Edwards, Laureano de la Vega. Cell Death Differ 2021
11
45

Dual specificity kinase DYRK3 couples stress granule condensation/dissolution to mTORC1 signaling.
Frank Wippich, Bernd Bodenmiller, Maria Gustafsson Trajkovska, Stefanie Wanka, Ruedi Aebersold, Lucas Pelkmans. Cell 2013
359
18


Emerging roles of DYRK2 in cancer.
Vasudha Tandon, Laureano de la Vega, Sourav Banerjee. J Biol Chem 2021
16
31

The novel ciliogenesis regulator DYRK2 governs Hedgehog signaling during mouse embryogenesis.
Saishu Yoshida, Katsuhiko Aoki, Ken Fujiwara, Takashi Nakakura, Akira Kawamura, Kohji Yamada, Masaya Ono, Satomi Yogosawa, Kiyotsugu Yoshida. Elife 2020
13
30

Synthesis and evaluation of β-carboline derivatives as potential monoamine oxidase inhibitors.
J Reniers, S Robert, R Frederick, B Masereel, S Vincent, J Wouters. Bioorg Med Chem 2011
60
14

β-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer's disease-related sites.
Danielle Frost, Bessie Meechoovet, Tong Wang, Stephen Gately, Marco Giorgetti, Irina Shcherbakova, Travis Dunckley. PLoS One 2011
105
14


A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication.
Peng Wang, Juan-Carlos Alvarez-Perez, Dan P Felsenfeld, Hongtao Liu, Sharmila Sivendran, Aaron Bender, Anil Kumar, Roberto Sanchez, Donald K Scott, Adolfo Garcia-Ocaña,[...]. Nat Med 2015
228
14


Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation.
Kunal Kumar, Peng Wang, Roberto Sanchez, Ethan A Swartz, Andrew F Stewart, Robert J DeVita. J Med Chem 2018
36
14

Low Expression of DYRK2 (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 2) Correlates with Poor Prognosis in Colorectal Cancer.
Haiyan Yan, Kaishun Hu, Wenjing Wu, Yu Li, Huan Tian, Zhonghua Chu, H Phillip Koeffler, Dong Yin. PLoS One 2016
20
20

Dual-specificity tyrosine-regulated kinase 2 is a suppressor and potential prognostic marker for liver metastasis of colorectal cancer.
Daisuke Ito, Satomi Yogosawa, Rei Mimoto, Shinichi Hirooka, Takashi Horiuchi, Ken Eto, Katsuhiko Yanaga, Kiyotsugu Yoshida. Cancer Sci 2017
20
20

Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics.
Dnyandev B Jarhad, Karishma K Mashelkar, Hong-Rae Kim, Minsoo Noh, Lak Shin Jeong. J Med Chem 2018
50
14

DYRK2 controls the epithelial-mesenchymal transition in breast cancer by degrading Snail.
Rei Mimoto, Naoe Taira, Hiroyuki Takahashi, Tomoko Yamaguchi, Masataka Okabe, Ken Uchida, Yoshio Miki, Kiyotsugu Yoshida. Cancer Lett 2013
53
14

Multiple functions of DYRK2 in cancer and tissue development.
Saishu Yoshida, Kiyotsugu Yoshida. FEBS Lett 2019
20
20

10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A.
Hannes Falke, Apirat Chaikuad, Anja Becker, Nadège Loaëc, Olivier Lozach, Samira Abu Jhaisha, Walter Becker, Peter G Jones, Lutz Preu, Knut Baumann,[...]. J Med Chem 2015
57
14

The protein kinase complement of the human genome.
G Manning, D B Whyte, R Martinez, T Hunter, S Sudarsanam. Science 2002
14

DYRK1A: a down syndrome-related dual protein kinase with a versatile role in tumorigenesis.
Amina Jamal Laham, Maha Saber-Ayad, Raafat El-Awady. Cell Mol Life Sci 2021
19
21

Forced expression of DYRK2 exerts anti-tumor effects via apoptotic induction in liver cancer.
Shiho Yokoyama-Mashima, Satomi Yogosawa, Yumi Kanegae, Shinichi Hirooka, Saishu Yoshida, Takashi Horiuchi, Toya Ohashi, Katsuhiko Yanaga, Masayuki Saruta, Tsunekazu Oikawa,[...]. Cancer Lett 2019
16
25

Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth.
Natividad Pozo, Cristina Zahonero, Paloma Fernández, Jose M Liñares, Angel Ayuso, Masatoshi Hagiwara, Angel Pérez, Jose R Ricoy, Aurelio Hernández-Laín, Juan M Sepúlveda,[...]. J Clin Invest 2013
86
14


Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 3 Loss Activates Purine Metabolism and Promotes Hepatocellular Carcinoma Progression.
Fei Ma, Yuekun Zhu, Xing Liu, Qingxin Zhou, Xuehui Hong, Chao Qu, Xing Feng, Yiyun Zhang, Qingbin Ding, Jiabao Zhao,[...]. Hepatology 2019
15
26

A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT.
Yousang Gwack, Sonia Sharma, Julie Nardone, Bogdan Tanasa, Alina Iuga, Sonal Srikanth, Heidi Okamura, Diana Bolton, Stefan Feske, Patrick G Hogan,[...]. Nature 2006
288
14

Identification of a DYRK1A-mediated phosphorylation site within the nuclear localization sequence of the hedgehog transcription factor GLI1.
Ben K Ehe, David R Lamson, Michael Tarpley, Rob U Onyenwoke, Lee M Graves, Kevin P Williams. Biochem Biophys Res Commun 2017
23
13

DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance.
Wolfgang Gruber, Martin Hutzinger, Dominik Patrick Elmer, Thomas Parigger, Christina Sternberg, Lukasz Cegielkowski, Mirko Zaja, Johann Leban, Susanne Michel, Svetlana Hamm,[...]. Oncotarget 2016
43
11


Structure-activity relationship study of beta-carboline derivatives as haspin kinase inhibitors.
Gregory D Cuny, Natalia P Ulyanova, Debasis Patnaik, Ji-Feng Liu, Xiangjie Lin, Ken Auerbach, Soumya S Ray, Jun Xian, Marcie A Glicksman, Ross L Stein,[...]. Bioorg Med Chem Lett 2012
46
11

3D-QSAR, design, synthesis and characterization of trisubstituted harmine derivatives with in vitro antiproliferative properties.
Céline Meinguet, Céline Bruyère, Raphaël Frédérick, Véronique Mathieu, Christelle Vancraeynest, Lionel Pochet, Julie Laloy, Jérémie Mortier, Gerhard Wolber, Robert Kiss,[...]. Eur J Med Chem 2015
15
20


Structure-Based Design and Synthesis of Harmine Derivatives with Different Selectivity Profiles in Kinase versus Monoamine Oxidase Inhibition.
Balázs Bálint, Csaba Wéber, Francisco Cruzalegui, Mike Burbridge, Andras Kotschy. ChemMedChem 2017
17
17

Structure-Activity Relationships and Biological Evaluation of 7-Substituted Harmine Analogs for Human β-Cell Proliferation.
Kunal Kumar, Peng Wang, Ethan A Swartz, Susmita Khamrui, Cody Secor, Michael B Lazarus, Roberto Sanchez, Andrew F Stewart, Robert J DeVita. Molecules 2020
8
37

Inhibitors of dual-specificity tyrosine phosphorylation-regulated kinases (DYRK) exert a strong anti-herpesviral activity.
Corina Hutterer, Jens Milbradt, Stuart Hamilton, Mirko Zaja, Johann Leban, Christophe Henry, Daniel Vitt, Mirjam Steingruber, Eric Sonntag, Isabel Zeitträger,[...]. Antiviral Res 2017
17
17


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.